Resolution of western blot-indeterminate and high risk seronegative blood donors by PCR.

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Resolution of western blot-indeterminate and high risk seronegative blood donors by PCR.

Int Conf AIDS. 1990 Jun 20-23;6(1):136 (abstract no. Th.A.12). Unique Identifier : AIDSLINE ICA6/10001290
Eble B; Busch M; Hurt M; Nason M; Garner J; Guiltinan A; Vyas G; Khayam-Bashi H; University of California, San Francisco, California, USA

Abstract: OBJECTIVE: Employ polymerase chain reaction amplification (PCR) as a confirmatory assay in order to resolve HIV or HTLV western blot-indeterminate serological results and as a means of screening high-risk seronegative individuals for occult HIV infection. METHODS: Peripheral blood mononuclear cell preparations from selected Northern California blood donors were lysed and subjected to PCR amplification for HIV gag gene or HTLV pol gene sequences, followed by solution hybridization with appropriate radiolabeled probes. The results of all HIV blot-indeterminate and a random sampling of high-risk seronegative samples were verified by established HIV virus culture methods, and negative PCR results were also verified by HLA coamplification. High-risk seronegatives included sexual partners of seropositive individuals and others. RESULTS: Of 5 HTLV and 21 HIV blot-indeterminate samples tested, none were positive by PCR. Only one of 21 high-risk seronegative samples was PCR positive for HIV infection. In contrast, all of a panel of 17 HIV seropositives or 15 of 16 HTLV seropositive control samples were positive by PCR. CONCLUSIONS: The PCR test with HLA coamplification appears useful in confirming the absence of viral infection in the vast majority of blood donors of blot-indeterminate serological status, and in many high-risk seronegative individuals.

Keywords: *Blood Donors *Blotting, Western Human HIV Infections/*DIAGNOSIS Nucleic Acid Hybridization *Polymerase Chain Reaction Risk Factors ABSTRACT
901230
M90C3706

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .